Trial to Compare Intra-individually the Efficacy and Tolerance of Oleogel-S10 Versus Moist Wound Healing Dressing Alone in Accelerating the Epithelialization of Split Thickness Skin Graft Donor Sites

NCT ID: NCT01294254

Last Updated: 2015-04-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 24 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2010-04-30
• Study Completion Date: 2010-11-30

Brief Summary

In this study the wound reepithelialization of that part of the skin graft donor site, which is treated with Oleogel-S10 compared to that part of the wound, which is covered by moist wound healing dressing alone will be investigated.

Detailed Description

As a first step, an adequate size of the wound healing dressing (Mepilex) is taken and cut in half. Then, half of the SSG (split skin graft) wound is covered conventionally by applying one half of the Mepilex cut. Afterwards Oleogel-S10 is applied to the other half of the Mepilex cut, which is used to cover the other half of the SSG wound. Both parts of the Mepilex dressings are then covered by an additional conventional dressing.

Oleogel-S10 is always applied to the same part of the SSG wound for each patient, respectively, depending on the randomization of the patient, either towards the periphery of the body, i.e. the lower part of the leg, or towards the centre part of the body, i.e. the upper part of the leg. In order to avoid a confusion about which part has to be treated with Oleogel-S10, the healthy skin next to the SSG wound will be marked with ink for indication of the Oleogel-treated part of the wound.

Each day during the treatment period, whenever the wound dressing is changed, a clinical examination and assessment of the progress of epithelialization of the SSG wound will be conducted, including evaluation of tolerance, and photos of the wound without dressing will be taken.

A blinded assessment of the efficacy is conducted by two independent investigators using the macro-photos of every day, when wound dressings were changed, and a final examination is done. In this assessment, the third part of the SSG wound that is in between the left and right parts is neglected.

Conditions

Accelerating the Epithelialization of Split Thickness Skin Graft

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: SINGLE

Study Groups

experimantal: wound site will be treated with Oleogel-S10

The patients will be randomised in a ratio of 1:1 with regard to the part of the skin graft donor site that is treated with Oleogel-S10.

Arm A: application of Oleogel-S10 towards the periphery of the body, i.e. the lower part of the leg

Arm B: application of Oleogel-S10 towards the centre part of the body, i.e. the upper part of the leg

• Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)
• Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

Group Type: EXPERIMENTAL

Oleogel-S10

Intervention Type: DRUG

Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)

Moist wound healing dressing alone

Treatment with moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

Group Type: ACTIVE_COMPARATOR

Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

Intervention Type: PROCEDURE

wound is covered conventionally by applying one half of the Mepilex cut

Interventions

Oleogel-S10

Oleogel-S10 on one half of the skin graft donor site (each time when the wound dressing is changed during a time period of 14 days, normally once daily)

Intervention Type: DRUG

Moist wound healing dressings alone (Mepilex) on the other half of the skin graft donor site

wound is covered conventionally by applying one half of the Mepilex cut

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

Patients may participate in the study if they have/are

• Patients aged 18-95 years who have provided written informed consent.
• Patients requiring skin grafting due to burns, trauma, chronic venous ulcers, or surgical removal of cutaneous malignancies with a donor site expected to be between 8 and 200 cm2 on a non-articulated area.
• Patient is prepared to comply with all study requirements, including the following:

• Application of Oleogel-S10 on the SSG at every change of wound dressing;
• Regular clinic visits during the treatment period, and follow-up period.
• Negative pregnancy test of women of childbearing potential performed within 7 days prior to the start of treatment.
• Women of childbearing potential must agree to use an effective method of contraception (Pearl-Index < 1, e.g. hormonal contraception including the combined oral contraceptive pill, the transdermal patch, and the contraceptive vaginal ring, intrauterine devices or sterilization) during treatment and for at least 6 months thereafter.
• Men must agree to use an effective method of contraception during treatment and for at least 6 months thereafter.

Exclusion Criteria

Patients will be excluded from the study if they have/are

• burns involving more than 15% of their total body area;
• sepsis, haemodynamic instability requiring pressor support or positive blood microbiology cultures within 48h of surgery;
• inhalation injury requiring artificial respiratory assistance;
• requiring skin grafts following removal of suspicious skin lesions;
• received treatment with systemic steroids during the 30 days prior to surgery;
• uncontrolled diabetes or diabetic ulcers;
• diseases or conditions that could, in the opinion of the Investigator, interfere with the assessment of safety, tolerance or efficacy;
• previously skin grafts harvested from the area to be studied;
• a skin disorder that is chronic or currently active and which the Investigator considers will adversely affect the healing of the acute wounds or involves the areas to be examined in this trial;
• a history of clinically significant hypersensitivity to any of the drugs or surgical dressings to be used in this trial;
• known multiple allergic disorders;
• taking, or have taken, any investigational drugs within 3 months prior to the screening visit;
• undergoing investigations or changes in management for an existing medical condition;
• not likely to complete the trial for whatever reason.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 95 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Birken AG

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Hans Robert Metelmann, Prof. Dr. med.

Role: PRINCIPAL_INVESTIGATOR

University Hospital of Ernst-Moritz-Arndt-University Greifswald

Locations

Universitäts-Hautklinik Freiburg

Freiburg im Breisgau, , Germany

Universitätsklinikum der Ernst-Moritz-Arndt-Universität Greifswald

Greifswald, , Germany

Countries

Germany

References

Metelmann HR, Brandner JM, Schumann H, Bross F, Fimmers R, Bottger K, Scheffler A, Podmelle F. Accelerated reepithelialization by triterpenes: proof of concept in the healing of surgical skin lesions. Skin Pharmacol Physiol. 2015;28(1):1-11. doi: 10.1159/000357501. Epub 2014 Jul 15.

Reference Type: RESULT

PMID: 25034442 (View on PubMed)

Other Identifiers

BSH-10

Identifier Type: -

Identifier Source: org_study_id